NCT01250912 - Imaging With a Radio Tracer to Guide VT Ablations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

July 1, 2019

Study Completion Date

July 1, 2019

Conditions

Ventricular TachycardiaArrhythmia

Interventions

DRUG

123I-metaiodobenzylguanidine

FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128\_128 matrix) will be acquired beginning 15 minutes after tracer injection.

Trial Locations (1)

21201

University of Maryland Medical Center, EP Lab, Rm. N3W77, Baltimore